Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear

Archives of General Psychiatry

Volumn 61, Issue 11, 2004, Pages 1136-1144

  Ressler, Kerry J ^a,b   Rothbaum, Barbara O ^a   Tannenbaum, Libby ^c   Anderson, Page ^c   Graap, Ken ^c   Zimand, Elana ^c   Hodges, Larry ^d   Davis, Michael ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c Virtually Better Inc   (United States)

^d UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; NOOTROPIC AGENT; PLACEBO;

ACROPHOBIA; ADULT; ANXIETY DISORDER; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ELECTRODERMAL RESPONSE; FEAR; FEMALE; HUMAN; MALE; PHOBIA; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VIRTUAL REALITY;

ADULT; COMBINED MODALITY THERAPY; CYCLOSERINE; DESENSITIZATION, PSYCHOLOGIC; DOUBLE-BLIND METHOD; EXTINCTION, PSYCHOLOGICAL; FEAR; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOBIC DISORDERS; PILOT PROJECTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 4644355629     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.61.11.1136     Document Type: Article

References (49)

1. Schatzberg A, Nemeroff CB. Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1998.
2. Otto M. Learning and "unlearning" fears: preparedness, neural pathways, and patients. Biol Psychiatry. 2002;52:917-920.
3. Foa E, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry. 2002;52:987-997.
4. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA. 2000;283:2529-2536.
5. Marks I, Swinson R, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry. 1993;162:776-787.
6. Sheinin A, Shavit S, Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology. 2001;41:151-158.
7. Hood W, Compton R, Monahan J. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett. 1989;98:91-95.
8. Flood J, Morley J, Lanthorn T. Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur J Pharmacol. 1992;221:249-254.
9. Lelong V, Dauphin F, Boulouard M. RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology. 2001;41:517-522.
10. Monahan JB, Handelmann GE, Hood WF, Cordi AA. D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav. 1989;34:649-653.
11. Tsai G, Falk W, Gunther J, Coyle J. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999;156:467-469.
12. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology. 1996;46:420-424.
13. Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22:2343-2351.
14. Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci. 2003;117:341-349.
15. Rescorla R. Experimental extinction. In: Klein S, ed. Handbook of Contemporary Learning Theories. Mahwah, NJ: Lawrence Erlbaum Associates; 2001:119-154.
16. Bouton M. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry. 2002;52:976-986.
17. Myers KM, Davis M. Behavioral and neural analysis of extinction. Neuron. 2002;36:567-584.
18. Falls WA, Miserendino MJ, Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci. 1992; 12:854-863.
19. Davis M, Myers KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry. 2002;52:998-1007.
20. Rothbaum BO, Hodges LF, Kooper R, Opdyke D, Williford JS, North M. Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia. Am J Psychiatry. 1995;152:626-628.
21. Rothbaum BO, Hodges L, Smith S, Lee JH, Price L. A controlled study of virtual reality exposure therapy for the fear of flying. J Consult Clin Psychol. 2000;68:1020-1026.
22. Rothbaum BO, Hodges LF, Ready D, Graap K, Alarcon RD. Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. J Clin Psychiatry. 2001;62:617-622.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
24. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry. 1992;49:624-629.
25. Cohen D. Comparison of self-report and overt-behavioral procedures for assessing acrophobia. Behav Ther. 1977;8:17-23.
26. Abelson J, Curtis G. Cardiac and neuroendocrine responses to exposure therapy in height phobies: desynchrony within the "physiological response system." Behav Res Ther. 1989;27:561-567.
27. Beck A, Ward C, Mendelsohn M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
28. Spielberger C, Gorsuch R, Lushene R. Manual for the State-Trait Anxiety Inventory (Self-Evaluation Questionnaire). Palo Alto, Calif: Consulting Psychologists Press; 1970.
29. Grillon C, Hill J. Emotional arousal does not affect delay eyeblink conditioning. Brain Res Cogn Brain Res. 2003;17:400-405.
30. Storm H, Myre K, Rostrup M, Stokland O, Lien MD, Raeder JC. Skin conductance correlates with perioperative stress. Acta Anaesthesiol Scand. 2002;46:887-895.
31. Lader MH. Palmar skin conductance measures in anxiety and phobic states. J Psychosom Res. 1967;11:271-281.
32. Tsai G, Falk W, Gunther J. A preliminary study of D-cycloserine treatment in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1998;10:224-226.
33. Goff D, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56:21-27.
34. D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry. 2000;47:450-462.
35. Fakouhi T, Jhee S, Sramek J, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol. 1995;8:226-230.
36. Randolph C, Roberts J, Tierney MC, Bravi D, Mourandian MM, Chase TN. D-cycloserine treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord. 1994; 8:198-205.
37. van Berckel BN, Lipsch C, Gispen-de Wied C, Wynne HJ, Blankenstein MA, van Ree JM, Kahn RS. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl). 1998;138:190-197.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association: 1994.
39. Santini E, Muller RU, Quirk GJ. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci. 2001; 21:9009-9017.
40. Matsuoka N, Aigner TG. D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys. J Pharmacol Exp Ther. 1996;278:891-897.
41. Thompson LT, Moskal JR, Disterhoft JF. Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature. 1992;359:638-641.
42. Quartermain D, Mower J, Rafferty M, Herting R, Lanthorn T. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;257:7-12.
43. Miserendino MJD, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature. 1990;345:716-718.
44. Kim J, DeCola J, Landeira-Fernandez J, Fanselow M. N-methyl-D-aspartate receptor antagonist APV blocks acquisition but not expression of fear conditioning. Behav Neurosci. 1991;105:126-133.
45. Baker JD, Azorlosa JL. The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behav Neurosci. 1996;110:618-620.
46. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63-69.
47. Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev. 2004;3:2.
48. Boje KM, Wong G, Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res. 1993;603:207-214.
49. O'Brien C, Childress A, McLellan A, Ehrman R. Classical conditioning in drug-dependent humans. Ann N Y Acad Sci. 1992;654:400-415.